Cipla introduces 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India

RT-Direct test protocol does not require any RNA extraction process, making it faster and helps deliver results in just 45 minutes.

Published On 2022-05-10 11:07 GMT   |   Update On 2022-05-10 11:08 GMT

Mumbai: Pharma major, Cipla Limited, today announced the commercialisation of 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd.

With this Cipla is expanding its diagnostics offering to bring more advance and innovative products. Cipla will be responsible for the distribution of RT Direct kits in India and has commenced supply of the same.

This kit is validated at the Indian Council of Medical Research (ICMR) approved Centre.

It is based on the 'gold standard RT-PCR method with coverage of three target genes specific to SARS-COV-2 along with IC, which is much advanced than others having 1 or 2 target genes. This greatly increases the sensitivity of the RTPCR test. RT-Direct test protocol does not require any RNA extraction process, making it faster and helps deliver results in just 45 minutes.

It will also increase the throughput of any testing lab by threefold compared to the normal RT-PCR test protocol time of 120-150 minutes.

Read also: Cipla Health unveils Evexpert, women's feminine hygiene range

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News